Generic Uloric Availability

Uloric is a brand name of febuxostat, approved by the FDA in the following formulation(s):

ULORIC (febuxostat - tablet;oral)

  • Manufacturer: TAKEDA PHARMS USA
    Approval date: February 13, 2009
    Strength(s): 40MG, 80MG [RLD]

Has a generic version of Uloric been approved?

No. There is currently no therapeutically equivalent version of Uloric available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Uloric. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • 2-arylthiazole derivatives and pharmaceutical composition thereof
    Patent 5,614,520
    Issued: March 25, 1997
    Inventor(s): Kondo; Shiro & Fukushima; Hisashi & Hasegawa; Masaichi & Tsuchimoto; Masahiro & Nagata; Ikuo & Osada; Yoshio & Komoriya; Keiji & Yamaguchi; Hisao
    Assignee(s): Teijin Limited
    Pharmaceutical compositions for treating gout or hyperuricemia and containing a new categorized compound, i.e. 2-arylthiazole derivatives, as an active ingredient, are provided. The 2-arylthiazole derivatives in the present invention are represented by the following formula (I): ##STR1## wherein Ar is an unsubstituted or substituted pyridyl, thienyl, furyl, naphthyl or phenyl group; X is a hydrogen atom, alkyl group or carboxyl group which may be protected, and Y is a hydrogen atom, alkyl group, or a hydroxyl or carbonyl group which may be protected. Furthermore, novel compounds included in the 2-arylthiazole derivatives and pharmaceutically acceptable salts thereof are provided.
    Patent expiration dates:
    • March 25, 2019
      ✓ 
      Patent use: CHRONIC MANAGEMENT OF HYPERURICEMIA IN PATIENTS WITH GOUT. NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same
    Patent 6,225,474
    Issued: May 1, 2001
    Inventor(s): Matsumoto; Koichi & Watanabe; Kenzo & Hiramatsu; Toshiyuki & Kitamura; Mitsutaka
    Assignee(s): Teijin Limited
    The present invention provides a technique of selectively producing a desired polymorph of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid. The present invention also provides a method of producing various polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid, which comprises crystallizing under the conditions defined by a specific temperature and a composition of a mixed solvent of methanol and water, and polymorphs obtained by the method. The present invention further provides a method of producing the other polymorphs or amorphous compounds by drying a specific polymorph under a reduced pressure with heating, and the other polymorphs or amorphous compounds obtained by the method.
    Patent expiration dates:
    • June 18, 2019
      ✓ 
      Drug substance
  • Solid preparation containing single crystal form
    Patent 7,361,676
    Issued: April 22, 2008
    Inventor(s): Iwai; Michio & Nakamura; Kazuhiro & Dohi; Masahiko & Mochizuki; Hiroko & Mochizuki; Seiji
    Assignee(s): Teijin Limited
    There are provided a solid preparation containing a single crystal of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid, an excipient and a disintegrating agent, and a method for producing the same.
    Patent expiration dates:
    • March 8, 2024
      ✓ 
      Drug product
  • Methods for concomitant treatment of theophylline and febuxostat
    Patent 8,372,872
    Issued: February 12, 2013
    Assignee(s): Takeda Pharmaceuticals U.S.A., Inc.
    Co-administration of febuxostat and theophylline to a hyperuricemic patient suffering from gout is disclosed.
    Patent expiration dates:
    • September 8, 2031
      ✓ 
      Patent use: USE OF FEBUXOSTAT FOR THE MANAGEMENT OF HYPERURICEMIA IN PATIENTS SUFFERING FROM GOUT AND, WHEN USED WITH THEOPHYLLINE WITHOUT THE NEED FOR DOSE ADJUSTMENT OF THEOPHYLLINE

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • February 13, 2014 -

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web4)